[Renal osteodystrophy(II)].

Abstract

Renal bone disease represents one of the major complications of end-stage renal disease, accounting for the numerous and various changes at bone level, determined by abnormal calcium and phosphorus homeostasis and by changes in calcitriol and PTH synthesis. PTH represents as well a major uraemic toxin, exerting profound systemic effects, particularly at the cardiovascular level. PTH synthesis is mainly controlled by changes in calcium-phosphorus balance and calcitriol production by the kidneys. Several others factors are important in the development of secondary hyperparathyroidism: acidosis, autonomisation of PTH secretion and peripheral (target-organ) resistance to PTH actions. Although bone biopsy represents the definitive diagnostic test to differentiate between osteitis fibrosa, low-turnover bone disease and bone involvement unrelated to disturbed calcium metabolism (i.e. beta 2-microglobulin-related amyloidosis), plasma intact PTH generally exhibits a reasonably good relation with bone histology parameters. Moreover serum bone-specific alkaline phosphatase isoenzyme, serum pyridinoline and the novel serum markers for bone turnover are highly specific and correlate with bone histomorphometry parameters, so that, preventive and therapeutic strategies should be re-evaluated based solely on biochemical parameters.

• Authors: A Covic, L Florea, C Ungureanu, M Covic
• Journal: Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi (Rev Med Chir Soc Med Nat Iasi) 2000 Oct-Dec Vol. 104 Issue 4 Pg. 21-5 ISSN: 0048-7848 [Print] Romania
• Vernacular Title: Osteodistrofia renală (II).
• PMID: 12089954 (Publication Type: Journal Article, Review)

Chemical References

• Parathyroid Hormone

Topics

• Chronic Kidney Disease-Mineral and Bone Disorder (diagnostic imaging, metabolism, therapy)
• Combined Modality Therapy
• Humans
• Parathyroid Hormone (metabolism)
• Radiography